Transfusion and Apheresis Science最新文献

{"title":"Effects of multiple apheresis platelet donations for the iron nutrition condition and platelet parameters of blood donors in China: A meta-analysis study","authors":"Quan Sun ,&nbsp;Liying Wu ,&nbsp;Yao Shen ,&nbsp;Le Wang ,&nbsp;Xiujuan Shen","doi":"10.1016/j.transci.2024.104043","DOIUrl":"10.1016/j.transci.2024.104043","url":null,"abstract":"<div><h3>Background</h3><div>Apheresis platelets is a common platelets collection method with high purity and relatively few adverse reactions. This study aimed to explore the effects of multiple apheresis platelet donations on the condition of iron nutrition and platelet parameters of donors in China.</div></div><div><h3>Methods</h3><div>Eligible studies were selected from PubMed, EMBASE, Wanfang, CQVIP, and the Chinese National Knowledge Infrastructure (CNKI) databases. Pooled serum ferritin (SF), serum iron (SI), transferrin (TRF), soluble transferrin receptor (sTfR), platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and platelet crit (PCT) were analyzed by weighted mean difference (WMD). Heterogeneity was detected by the Cochran Q test and <em>I</em>² statistical test.</div></div><div><h3>Results</h3><div>Pooled SF (WMD =-20.837, 95 % CI = −26.403 - −15.271) and SI (WMD = −3.828, 95 % CI = −6.516 - −1.139) were significantly decreased; while TRF (WMD = 0.821, 95 % CI = 0.271–1.371) and sTfR (WMD = 0.846, 95 % CI = 0.442–1.250) were increased by multiple apheresis platelet donations. PLT (WMD = 14.894, 95 % CI = 2.574–27.215) and PCT (WMD = 0.035, 95 % CI = 0.005–0.064) were increased, but MPV (WMD = −0.359, 95 % CI = −0.571 - −0.147) was reduced by multiple donations. Subgroup analysis indicated study design is a source of heterogeneity.</div></div><div><h3>Conclusion</h3><div>Multiple apheresis platelets could lead to iron deficiency and suppress platelet function in comparison with first-time apheresis platelets.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104043"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of ruxolitinib in the management of acute GVHD","authors":"Sinem Namdaroglu ,&nbsp;Emine Hidayet ,&nbsp;Muruvvet Seda Aydin ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Ilhami Berber ,&nbsp;Olgu Erkin Cinar ,&nbsp;Gulsum Ozet ,&nbsp;Seda Yilmaz ,&nbsp;Merve Apaydin ,&nbsp;Mehmet Sinan Dal ,&nbsp;Serdal Korkmaz ,&nbsp;Abdulkadir Basturk ,&nbsp;Turgay Ulaş ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104055","DOIUrl":"10.1016/j.transci.2024.104055","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Following an allogeneic hematopoietic stem cell transplant (allo-HSCT), a primary cause of morbidity and mortality is still steroid-refractory acute graft-versus-host disease (SR-aGVHD). Recently, ruxolitinib, an oral inhibitor of JAK1 and JAK2, was approved for use in individuals suffering from SR-aGVHD. This study aimed to analyze the efficacy and toxicity of ruxolitinib in the real world.</div></div><div><h3>Material and methods</h3><div>In the present study, we investigated the effectiveness and toxicity of ruxolitinib in patients with SR-aGVHD using a multicenter retrospective analysis. We enrolled 23 patients between 2018 and 2024 who received ruxolitinib treatment for SR-aGVHD.</div></div><div><h3>Results</h3><div>The first response was acheived in a median of 28 days (range, 12–150). The overall response rate (ORR) for ruxolitinib therapy was 43.5 % (10/23) after one month and 61 % (14/23) after two months, respectively. The median overall survival was 69 months. Reactivation of cytomegalovirus (26.1 %) and grade 3–4 anemia (30.4 %) were the two main side effects of ruxolitinib therapy. Seven patients (30.4 %) passed away following a follow-up of a median of six months (range 1–70). The reasons for death included sepsis (n = 2, 28.6 %), progression of aGVHD (n = 3, 42.8 %), and other reasons.</div></div><div><h3>Conclusion</h3><div>Ruxolitinib has an ORR of 61 % for SR-aGVHD, making it a safe and effective therapy choice in real-world settings.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104055"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term complications, survival and mortality in splenectomised adult transfusion-dependent thalassemia patients","authors":"Urmimala Bhattacharjee ,&nbsp;Alka Khadwal ,&nbsp;Charanpreet Singh ,&nbsp;Deepak Bansal ,&nbsp;Amita Trehan ,&nbsp;Thakur Deen Yadav ,&nbsp;Arihant Jain ,&nbsp;Gaurav Prakash ,&nbsp;Prashant Sharma ,&nbsp;Reena Das ,&nbsp;Pankaj Malhotra","doi":"10.1016/j.transci.2024.104064","DOIUrl":"10.1016/j.transci.2024.104064","url":null,"abstract":"<div><h3>Background</h3><div>Splenectomy is frequently performed in transfusion-dependent thalassemia (TDT) patients to lower blood transfusion needs but is associated with significant long-term complications, including sepsis, thrombosis, and pulmonary hypertension. This study examines the long-term complications, survival rates, and causes of mortality among adult patients with TDT who have undergone splenectomy in a low and middle-income country (LMIC).</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on 103 adult TDT patients (≥18 years) who underwent splenectomy between July 2013 and March 2024. Data collected included demographic and clinical characteristics, haematological parameters, transfusion requirements before splenectomy and at the last follow-up, survival rates, complications, and mortality causes.</div></div><div><h3>Results</h3><div>The median age at splenectomy was 12 years (range 5–34). The majority (98 %) underwent open splenectomy. The yearly transfusion volume decreased from 276.7 ml/kg/year pre-splenectomy (range 207–433) to 146.2 (range 0–252.9) post-splenectomy at the last follow-up, p &lt; 0.0001. Three patients were completely transfusion-free at the last follow-up. Complications included pulmonary hypertension in 10 (9.7 %), thrombosis in 5 (4.8 %), and overwhelming post-splenectomy infection (OPSI) in 4 (3.9 %). The iron-overload-related complications included cardiomyopathy in 17 (16.5 %), endocrinopathy in 56 (54.3 %), chronic liver disease in 15 (14.5 %) and hepatocellular carcinoma in 2 (0.9 %). The 15-year post-splenectomy overall survival (OS) was 84.7 % (95 % CI- 77.3 % - 92.8 %), with 17 deaths (16.5 %) recorded. Iron-overload-related cardiomyopathy was the leading cause of death in 8 (53.3 %).</div></div><div><h3>Conclusion</h3><div>Splenectomy significantly reduces transfusion requirements in TDT patients but is associated with risks such as thrombosis, pulmonary hypertension, and OPSI. Long-term mortality is primarily driven by iron-overload-related cardiomyopathy.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104064"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alloanti-D induction in a rare RhD variant (DBT-2) case: Insights from serological and molecular biological testing","authors":"Zhiyuan Xu,&nbsp;Ye Zhang,&nbsp;Tianhong Miao,&nbsp;Tingting Liu,&nbsp;Xiaofei Li","doi":"10.1016/j.transci.2025.104083","DOIUrl":"10.1016/j.transci.2025.104083","url":null,"abstract":"<div><h3>Background</h3><div>The RhD antigen is the most immunogenic within the Rh blood group system， playing a pivotal role in clinic. The D variant phenotype is a rare occurrence, characterized by low expression of the D antigen or partial deletion of the RhD antigen on the surface of red blood cells (RBCs). For individuals with the D variant, transfusion with RhD-negative blood is crucial for ensuring transfusion safety.</div></div><div><h3>Case presentation</h3><div>We present a case of a 63-year-old Han Chinese female, identified as a D variant phenotype without a history of blood transfusion but with a history of pregnancy. Pre-transfusion testing revealed the presence of alloanti-D antibodies. Genetic analysis confirmed the patient's genotype as <em>RHD-CE (5−9)-D,</em> and her phenotype was classified as DBT-2.</div></div><div><h3>Conclusion</h3><div>This report marks the first case in China of anti-D alloimmunization in patients with the D variant. Both serological and molecular detection of the D variant are essential to ensure the safety of blood transfusions.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104083"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143148999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of anti-f(ce) antibody identified with unknown autoantibody from ABO discrepancy in a patient with liver cell carcinoma","authors":"Hyorin Kim,&nbsp;Suk Won Seo,&nbsp;Han Joo Kim,&nbsp;Sang-Hyun Hwang,&nbsp;Heung-Bum Oh,&nbsp;Dae-Hyun Ko","doi":"10.1016/j.transci.2024.104046","DOIUrl":"10.1016/j.transci.2024.104046","url":null,"abstract":"<div><div>The Rh blood type has 57 antigens, including D, C, E, c, and e. This blood type is clinically significant, alongside the ABO blood type. The anti-f(ce) antibody is an unexpected antibody that targets an antigen composed of the c and e antigens. We would like to report a case of the anti-f(ce) antibody discovered during an investigation of an ABO discrepancy. A 63-year-old man diagnosed with liver cell carcinoma was hospitalized for endoscopic variceal ligation due to esophageal varix. To prepare for the possibility of transfusion during the procedure, an ABO blood type test was conducted, resulting in B and O in cells and serum/plasma typing, respectively. The unexpected antibody identification test revealed the presence of the anti-f(ce) antibody. The Rh phenotype of the B cells used in the ABO serum/plasma typing test was determined to be ce. The anti-f(ce) antibody present in the patient’s serum reacted with the B cells in the ABO serum/plasma typing test. To our knowledge, this is the first report of anti-f(ce) causing ABO discrepancy in Korea, and only the second reported case worldwide. We hope that our case report on the identification of the rare anti-f(ce) antibody from an ABO discrepancy will be beneficial for transfusion medicine laboratories.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104046"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Message from the new WAA President","authors":"Joseph Schwartz","doi":"10.1016/j.transci.2024.104047","DOIUrl":"10.1016/j.transci.2024.104047","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104047"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging trends and controversies in GVHD management: Bridging research and clinical practice","authors":"Fevzi Altuntas","doi":"10.1016/j.transci.2024.104049","DOIUrl":"10.1016/j.transci.2024.104049","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104049"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of a young HoFH patient during pregnancy using Lipoprotein Apheresis (whole blood): A novel experience","authors":"Claudia Stefanutti ,&nbsp;Giuseppina Perrone ,&nbsp;Paola Galoppi ,&nbsp;Giovanna Zeppa ,&nbsp;Valentina Demarco","doi":"10.1016/j.transci.2024.104062","DOIUrl":"10.1016/j.transci.2024.104062","url":null,"abstract":"<div><div>The pregnancy of a patient with homozygous familial hypercholesterolemia (HoFH) represents a challenge in the clinical setting due to the high cardiovascular risk of the mother and maternal-fetal morbidity. The lipid lowering drugs are generally contraindicated and lipoprotein apheresis (LA) is the only accepted treatment in HoFH pregnant woman. Liposorber D, an LA technique on whole blood, has good efficacy, safety, and short operative time.</div><div>We present a 31-year-old Caucasian pregnant woman with HoFH clinical phenotype on lipid-lowering treatment with Lomitapide and Evolocumab, discontinued during pregnancy. In multidisciplinary team it was decided to submit the patient to LA throughout the pregnancy. Liposorber D sessions (a whole blood technique) were performed on a strict weekly frequency. The treatment resulted in massive decrease of total cholesterol (TC) and LDL cholesterol (LDL-c), with no significant side effects. The pregnancy presented a normal course and a cesarean section was performed on clinical indications unrelated to the use of LA. She gave birth to a healthy male child at 37 weeks of gestation.</div><div>LA is considered the only effective, safe and accepted therapy during HoFH pregnancy. This is the first reported case of successful pregnancy treated with Liposorber D, a whole blood LA technique. LA with dextran sulfate has been an effective and safe choice for the mother and fetus. Furthermore it was reasonably well tolerated from the beginning of pregnancy management to its conclusion.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104062"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are mesenchymal stem cells still effective in acute GvHD management?","authors":"Bahar Uncu Ulu ,&nbsp;Ipek Yonal Hindilerden ,&nbsp;Tugce Nur Yigenoglu ,&nbsp;Tarik Onur Tiryaki ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Gulten Korkmaz ,&nbsp;Sinem Namdaroglu ,&nbsp;Elif Aksoy ,&nbsp;Serdal Korkmaz ,&nbsp;Mert Seyhan ,&nbsp;Seda Yilmaz ,&nbsp;Sevgi Kalayoglu Besisik ,&nbsp;Mehmet Sinan Dal ,&nbsp;Turgay Ulas ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104051","DOIUrl":"10.1016/j.transci.2024.104051","url":null,"abstract":"<div><h3>Objective</h3><div>Graft-versus-host disease (GvHD) is a common and serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly impacting transplant efficacy. In the treatment of GvHD, numerous therapeutic approaches have been explored, with mesenchymal stem cells (MSCs) emerging as a prominent immunomodulatory option. We aimed to evaluate efficacy and outcomes of using MSCs for steroid refractory acute GVHD (SR-aGvHD) management.</div></div><div><h3>Materials and methods</h3><div>We retrospectively analyzed data from 36 patients’ who received MSCs for treatment of SR-aGvHD following allo-HSCT between 2018 and 2024 from nine transplantation centers in Türkiye. The product consisted of umbilical cord-derived allogeneic MSCs, which were administered intravenously.</div></div><div><h3>Results</h3><div>Our cohort was at the median age of 39 years (range: 19–61 years), with aGvHD diagnosed at a median of two months after allo-HSCT. More than half of the patients (58.3 %) classified as high-grade aGvHD according to the Minnesota risk scoring. Cord blood-derived MSCs were administered at a median dose of 3.45 (range: 0.8–5) million MSCs/kg, with a median of 3th (range: 2–5) line treatment. The rate of responses exceeding partial response (PR) was approximately 20 % at the first month, increasing to 24 % at the second month. The six-month survival rate was 33 %, with 46 % of mortality attributed to sepsis and 12.5 % related to GvHD. Multivariate analysis indicated that increasing age (≥35 years) and lower platelet counts (≤75 x10⁹/L) were associated with higher mortality (p &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>MSC therapy has shown promising potential in improving response rates in aGvHD treatment, with efficacy enhanced by younger age and higher platelet counts.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104051"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of ibrutinib in the management of chronic GVHD","authors":"Mehmet Ali Erkurt ,&nbsp;Ahmet Sarici ,&nbsp;Abdulkadir Sahin ,&nbsp;Ilhami Berber ,&nbsp;Gulten Korkmaz ,&nbsp;Irfan Kuku ,&nbsp;Mehmet Sinan Dal ,&nbsp;Serdal Korkmaz ,&nbsp;Turgay Ulas ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104052","DOIUrl":"10.1016/j.transci.2024.104052","url":null,"abstract":"<div><h3>Objectives</h3><div>Chronic graft-versus-host disease (cGVHD) represents a significant adverse event that may ensue following allogeneic hematopoietic stem cell transplantation (Allo-HSCT). In patients resistant to corticosteroids, which is the first-line treatment for cGVHD, ibrutinib is being evaluated as a potential treatment option. In this study, we aimed to share the findings of our multicenter study regarding the outcomes of ibrutinib treatment in patients with corticosteroid-resistant cGVHD who had previously received multiple systemic therapies.</div></div><div><h3>Material and methods</h3><div>A retrospective analysis was conducted to examine the clinical characteristics and outcomes of patients who received ibrutinib treatment for corticosteroid-resistant cGVHD after Allo-HSCT.</div></div><div><h3>Results</h3><div>A total of 24 patients diagnosed with cGVHD who received ibrutinib treatment were included in the study. The median age of the patients was 34.5 (20–67). The included patients were followed for a median of 6 (1–30) months. All patients had stem cells collected from the peripheral blood. Fifty percent of the patients had multiple organ involvement, while the other 50 % had single organ involvement. The most frequently affected organs were skin and liver. On average, patients received four (3–5) lines of systemic therapy before ibrutinib treatment. At week 24 of ibrutinib treatment, 10 patients (41.7 %) had a complete response, and 10 patients (41.7 %) had a partial response; at week 48, 8 patients (33.3 %) had a complete response, and 10 patients (41.7 %) had a partial response. The most common hematological side effect after ibrutinib treatment was thrombocytopenia in 5 out of 24 patients, while the most common non-hematological side effect was CMV infection in 6 out of 24 patients.</div></div><div><h3>Conclusion</h3><div>In patients with corticosteroid-resistant cGVHD, ibrutinib treatment has been demonstrated to be an efficacious option exhibiting an elevated overall response rate and a tolerable side effect profile.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104052"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}